drugset / Trial / NCT06992440
Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension
Phase 2
Enrolling by invitation
78 enrolled
The Cleveland Clinic
National Heart, Lung, and Blood Institute (NHLBI) · collabThe Cleveland Clinic · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Randomized, triple-masked, parallel arm clinical trial of empagliflozin versus placebo in pulmonary arterial hypertension (PAH) participants on stable approved PAH-targeted medical therapy.
Timeline
- Start
- 2025-06-26
- Primary completion
- 2030-07
- Completion
- 2030-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Empagliflozin | Small molecule | 10 mg | Oral |